Multi-Peptide Protocol

Body Composition: Tesamorelin + AOD-9604

Tesamorelin is an FDA-approved 44-amino acid GHRH analog (marketed as Egrifta) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191) that was granted GRAS (Generally Recognized as Safe) status by the FDA as a food supplement ingredient but is not FDA-approved as a drug for any indication. This protocol discusses their combined use for body composition optimization.

Rationale for Combination

Tesamorelin and AOD-9604 are combined in body composition protocols because they target complementary aspects of fat metabolism through distinct mechanisms. The theoretical basis for their combination draws on their non-overlapping pathways for reducing adiposity while preserving lean mass.

Tesamorelin: GHRH-Mediated Lipolysis

Tesamorelin is a synthetic 44-amino acid analog of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a physiological pulsatile pattern, mimicking normal GH secretion rather than producing the supraphysiological levels seen with exogenous GH administration. Its primary mechanisms relevant to body composition include:

• Visceral adipose tissue reduction: Phase III clinical trials demonstrated a 15–18% reduction in visceral adipose tissue (VAT) as measured by CT scan after 26 weeks of treatment at 2 mg daily.[1]
• Pulsatile GH release: Unlike exogenous GH, Tesamorelin preserves the hypothalamic-pituitary feedback loop, producing GH pulses that more closely resemble physiological secretion patterns.[4]
• Lipid profile improvement: Clinical trials showed reductions in triglycerides and improvements in trunk fat-to-limb fat ratio in treated patients.[5]
• IGF-1 normalization: Tesamorelin raises IGF-1 levels into the normal physiological range, supporting downstream lipolytic and anabolic signaling.[1]

AOD-9604: Targeted Lipolytic Fragment

AOD-9604 is a modified peptide fragment corresponding to amino acids 176–191 of human growth hormone, with an added tyrosine residue at the N-terminus. It was designed to retain the lipolytic (fat-burning) activity of GH while eliminating the growth-promoting and diabetogenic effects. Its mechanisms include:

• Lipolysis stimulation: AOD-9604 stimulates lipolysis (fat breakdown) in adipose tissue through a mechanism similar to GH but independent of the GH receptor, acting via the beta-3 adrenergic receptor pathway.[6]
• Lipogenesis inhibition: In addition to promoting fat breakdown, AOD-9604 inhibits lipogenesis (new fat formation), creating a dual anti-obesity effect.[7]
• No IGF-1 elevation: Unlike full-length GH, AOD-9604 does not significantly elevate IGF-1 levels, reducing the theoretical risk of IGF-1-mediated side effects.[6]
• No diabetogenic effect: Preclinical studies demonstrated that AOD-9604 does not impair glucose tolerance or produce insulin resistance, unlike full-length GH or the intact GH molecule.[7]

Per-Component Dosing

The following dosing information reflects commonly reported protocols in the clinical and compounding literature. Individual responses vary significantly, and dosing should always be guided by a supervising clinician.

Timing & Administration

Both Tesamorelin and AOD-9604 are best administered in a fasted state in the morning, ideally at least 30 minutes before consuming food. This timing optimizes the GH pulse induced by Tesamorelin and maximizes the lipolytic window of AOD-9604.

• Tesamorelin: Reconstitute per manufacturer instructions using the sterile water diluent provided with the Egrifta kit. Inject subcutaneously into the abdomen, rotating injection sites. Administer at the same time each day.
• AOD-9604: Reconstitute lyophilized powder with bacteriostatic water (BAC water). Inject subcutaneously into the abdomen or thigh in a fasted state. Can be administered at the same time as Tesamorelin but at a different injection site.
• Fasting window: Avoid food for at least 30 minutes after injection. Consuming carbohydrates or fats during this window may blunt the GH response triggered by Tesamorelin.
• Exercise timing: If training in the morning, administer both peptides 30–60 minutes before exercise for maximal synergy with exercise-induced GH release and lipolysis.

Cycle Structure

Tesamorelin Duration

• Clinical trials have studied Tesamorelin for 26–52 weeks of continuous use with established safety profiles[1][5]
• Can be used long-term if prescribed and monitored by a physician
• VAT reduction may plateau after 26 weeks; effects reverse upon discontinuation in clinical trial data

AOD-9604 Cycling

• Typically used in 12-week cycles followed by 4-week off periods
• No long-term continuous use data available
• Off-cycle periods allow receptor sensitivity to be maintained

Combined Protocol

• Weeks 1–12: Both Tesamorelin (2 mg daily) and AOD-9604 (250–500 mcg daily) administered concurrently
• Weeks 13–16 (off-cycle for AOD-9604): Continue Tesamorelin if prescribed; discontinue AOD-9604 for 4 weeks
• Repeat: Resume AOD-9604 for the next 12-week cycle if continuing the protocol
• Reassess body composition and laboratory markers at each cycle boundary before continuing

Expected Timeline

• Tesamorelin — 4 weeks: IGF-1 levels begin to normalize; subjective improvements in energy and sleep quality may be noted
• Tesamorelin — 12 weeks: Measurable reduction in visceral adipose tissue detectable on DEXA or CT imaging
• Tesamorelin — 26 weeks: Peak effect on visceral fat reduction (15–18% decrease in clinical trials)[1]
• AOD-9604 — 4–8 weeks: Lipolytic effects typically become noticeable; improvements in body composition and waist measurements
• Combined — 12 weeks: Optimal assessment point for the combination protocol; body composition analysis (DEXA) recommended

Complementary Lifestyle Factors

Peptide therapy for body composition produces the best results when combined with structured lifestyle interventions:

• Caloric deficit: A moderate caloric deficit (300–500 kcal/day below maintenance) enhances the lipolytic effects of both compounds. Aggressive caloric restriction is not recommended as it may suppress endogenous GH secretion.
• Resistance training: Structured resistance training (3–4 sessions per week) preserves lean mass during fat loss and amplifies the body recomposition effect. GH-mediated effects on lean tissue are optimized with mechanical stimulus.
• Protein intake: Consume at least 1.6 g/kg body weight of protein daily to support lean mass preservation and muscle protein synthesis during caloric deficit.[8]
• Sleep optimization: The majority of endogenous GH is released during slow-wave sleep. Aim for 7–9 hours of quality sleep per night. Poor sleep blunts both natural GH secretion and the pulsatile response to Tesamorelin.

Monitoring Guidance

Regular monitoring is essential during any GH-related peptide protocol. The following parameters should be assessed at baseline, 6 weeks, 12 weeks, and at each cycle boundary:

What to Track

• Body composition: DEXA scan preferred for accurate assessment of visceral fat, total body fat percentage, and lean mass. Waist circumference as a low-cost adjunct (measure at the level of the iliac crest).
• Waist circumference: Measure at baseline and every 4 weeks. A reduction of ≥2 cm at 12 weeks is a positive signal.
• Fasting glucose, insulin, and HbA1c: Tesamorelin can elevate glucose in approximately 4.5% of patients per the FDA label. Monitor at baseline, 6 weeks, and 12 weeks.[3]
• IGF-1: Measure at baseline and 4–6 weeks after initiation. Target the upper half of the age-adjusted normal range. Dose adjustment may be needed if IGF-1 exceeds the upper limit of normal.
• Lipid panel: Total cholesterol, LDL, HDL, and triglycerides at baseline and 12 weeks. Tesamorelin has been shown to improve triglyceride levels in clinical trials.[5]
• Liver function: AST, ALT, and GGT at baseline and 12 weeks. While hepatotoxicity is not a known effect, monitoring is prudent with any chronic peptide therapy.
• Injection site reactions: Document redness, swelling, pruritus, or induration at injection sites. Rotate sites to minimize local reactions.

When to Stop

• Any sign of allergic reaction (urticaria, angioedema, anaphylaxis)
• Fasting glucose consistently >126 mg/dL or HbA1c >6.5% (new-onset diabetes)
• IGF-1 levels persistently above the age-adjusted upper limit of normal
• New or worsening peripheral edema, arthralgia, or carpal tunnel symptoms
• Any suspected tumor growth, new mass, or unexplained weight gain
• Worsening of diabetic retinopathy or visual changes
• No measurable improvement in body composition after 12 weeks at full dose

Side Effects

Tesamorelin (per FDA Label)[3]

• Injection site reactions: Erythema, pruritus, pain, and irritation at the injection site (most common adverse event in clinical trials)
• Arthralgia: Joint pain reported in clinical trials, consistent with GH-mediated effects on connective tissue
• Peripheral edema: Fluid retention, typically mild, related to GH-induced sodium and water retention
• Glucose elevations: Approximately 4.5% of patients experienced elevated fasting glucose. HbA1c changes were generally modest.[3]
• Paresthesia: Tingling or numbness, related to fluid retention and possible carpal tunnel-like effects
• Myalgia: Muscle pain, generally mild and self-limiting

AOD-9604

• Injection site reactions: Mild redness, swelling, or discomfort at injection site (most commonly reported)
• Headache: Reported in some users, typically transient and resolving within the first week of use
• Generally well-tolerated: Available human data (primarily from Phase IIb obesity trials) suggest a favorable safety profile, though the data set is limited[9]
• No significant glucose effects: Unlike full-length GH, AOD-9604 has not demonstrated diabetogenic effects in preclinical or clinical studies[7]

Drug Interactions

No formal drug interaction studies have been conducted for the Tesamorelin + AOD-9604 combination. The following are considerations based on known pharmacology:

• Insulin and diabetes medications: Both Tesamorelin and (to a lesser extent) the GH pathway can affect glucose homeostasis. Patients on insulin, metformin, sulfonylureas, or other glucose-lowering agents require closer glucose monitoring. Dose adjustments of diabetes medications may be necessary.[3]
• Glucocorticoids: Chronic glucocorticoid use (prednisone, dexamethasone) may reduce the efficacy of Tesamorelin by suppressing the GH axis and promoting visceral fat deposition, counteracting the therapeutic goal.
• Thyroid medications: GH can increase the peripheral conversion of T4 to T3 and may unmask central hypothyroidism. Patients on levothyroxine may require thyroid function monitoring and dose adjustment.
• Other GH-releasing peptides: Concurrent use of other GHRH analogs (sermorelin), GH secretagogues (ipamorelin, MK-677), or exogenous GH with Tesamorelin may produce additive or supraphysiological GH/IGF-1 elevation. Combined use is generally not recommended without careful IGF-1 monitoring.
• Cortisone acetate and 11-beta-HSD1 inhibitors: Tesamorelin has been shown to modulate cortisol metabolism. Interactions with drugs affecting cortisol pathways are theoretically possible.

Educational Videos

The following lectures from Dr. Andrew Huberman provide relevant background on growth hormone physiology and fat loss mechanisms:

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. PMID: 18057338.
2. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334. PMID: 25038357.
3. FDA. Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. Revised 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s010lbl.pdf.
4. Falutz J, Allas S, Mamputu JC, et al. Long-term effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: two randomized clinical trials. AIDS. 2008;22(14):1719-1728. doi:10.1097/QAD.0b013e32830a5058. PMID: 18690162.
5. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, on visceral fat and metabolic parameters in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):T1-T8. doi:10.1210/jc.2009-2681.
6. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740. PMID: 11673764.
7. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. doi:10.4021/jem.v3i1-2.151.
8. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine. 2018;52(6):376-384. doi:10.1136/bjsports-2017-097608. PMID: 28698222.
9. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278. doi:10.1159/000053183. PMID: 11146367.
10. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology-Endocrinology and Metabolism. 2000;279(3):E501-E507. doi:10.1152/ajpendo.2000.279.3.E501. PMID: 10950816.
11. Adelaiye AB, Ahaneku JE. Changes in serum lipid profile following growth hormone administration: a review. African Journal of Biotechnology. 2006;5(12):1141-1146.
12. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology & Metabolism. 1997;82(3):727-734. doi:10.1210/jcem.82.3.3809. PMID: 9062473.